Mass ligand binding screening for receptor antagonists: prototype new drugs and blind alleys.
The ligand binding assay is a powerful tool in the search for antagonists for novel receptors, and for identification of novel classes of antagonists for well-known receptors. Ligand binding mass screening can be adapted for very high throughput. In order for mass screening to be useful, it is necessary to strictly define the binding characteristics for a compound to be considered a putative receptor antagonist. In practice, we have found that synthetic pursuit of a compound with a Ki of greater than or equal to 1 microM is likely to lead down a blind alley unless very good evidence for specificity is available. Even potent competitors for binding should be thoroughly evaluated in assays of biological activity before a synthetic program is initiated in earnest.
Burch
R M
RM
Nova Pharmaceutical Corporation, Baltimore, MD 21224.
D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D008024:Ligands; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors*
D008024:Ligands; D011956:Receptors, Cell Surface